Satraplatin for Locally Advanced Non-Small Cell Lung Cancer With Simultaneous Radiotherapy
Status:
Terminated
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
PURPOSE: This trial is designed to compare the combination of the investigational oral
cytotoxic drug, satraplatin, and radiation therapy for patients with locally advanced
Non-Small Cell Lung Cancer (NSCLC) with no prior chemotherapy or radiation therapy treatment.
Please refer to the Eligibility Criteria below for key inclusion and exclusion criteria.
WHAT IS SATRAPLATIN: Satraplatin is an oral, investigational anticancer drug that is a member
of the platinum-based class of chemotherapy drugs. Platinum-based drugs have been clinically
proven to be one of the most effective classes of anticancer therapies. Unlike the currently
marketed platinum-based drugs, satraplatin can be given orally.
RATIONALE: Intravenously administered platinum-based drugs are currently used in combination
with radiation therapy in the treatment of patients with locally advanced NSCLC. The purpose
of this Phase I trial is to determine a tolerable dose and schedule for the oral platinum
drug (satraplatin) when given to NSCLC patients throughout the course of their radiotherapy
treatment.